Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia
NCT ID: NCT00492232
Last Updated: 2010-07-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
135 participants
INTERVENTIONAL
2007-04-30
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia
NCT00237497
A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia
NCT00466193
Xyrem(Sodium Oxybate) and Ambien(Zolpidem Tartrate) in the Treatment of Chronic Insomnia.
NCT00383643
Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia
NCT00756002
Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.
NCT00247390
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Zolpidem is the most commonly prescribed hypnotic in the United States for patients suffering from insomnia.
The purpose of this study is to assess whether ramelteon therapy can facilitate the discontinuation of benzodiazepine therapy in long term users. Subject participation in this study is anticipated to be about 17 weeks.
Subjects were screened and enrolled in a 4-week placebo run-in period, may have been randomized to a 10-week double-blind treatment period, and may have completed with a 2-week open-label treatment period. In the double-blind treatment period, subjects were randomized to one of two treatments: either ramelteon 8 mg tablets taken orally once-daily with concomitant current zolpidem therapy or to placebo-matching tablets once daily with concomitant current zolpidem therapy. Subjects incrementally reduced zolpidem therapy by dose, frequency, or both for up to 10 weeks. Only those subjects who completed the double-blind treatment period and had achieved a 50% reduction in zolpidem therapy during the double-blind treatment period participated in the open-label treatment period in which 8 mg ramelteon was administered. Zolpidem consumed during the open-label treatment period was recorded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ramelteon 8 mg QD and current Zolpidem therapy
Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
Ramelteon and zolpidem
Ramelteon 8 mg, tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
Placebo QD and current Zolpidem therapy
Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
Placebo and zolpidem
Ramelteon placebo-matching tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ramelteon and zolpidem
Ramelteon 8 mg, tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
Placebo and zolpidem
Ramelteon placebo-matching tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has been prescribed zolpidem for difficulty in initiating sleep.
* Must report chronic use of zolpidem greater than or equal to10 mg therapy for a minimum of 3 months prior to entry into Period 1 of the study.
* Must have taken zolpidem greater than or equal to 10 mg therapy for at least 4 of 7 days each week of the 4 weeks immediately prior to entry into the double blind phase, Period 2.
* Expressed a willingness to discontinue zolpidem therapy.
* Habitual bedtime is between 9:00 PM and 1:00 AM based on sleep history.
* Negative test result for hepatitis B surface antigen and hepatitis C virus antibody.
* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
Exclusion Criteria
* Participated in any other investigational study and/or taken any investigational drug within 30 days prior to the first dose of run-in study medication.
* Sleep schedule changes required by employment (eg, shift worker) within 3 months prior to the first night of run-in study medication.
* History of fibromyalgia, history of seizures, sleep apnea, restless leg syndrome, periodic leg syndrome, chronic obstructive pulmonary disease, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder.
* History of drug addiction or drug abuse within the past 12 months.
* History of alcohol abuse within the past 12 months, as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition revised and/or regularly consumes more than 2 alcoholic drinks per day.
* Current significant hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological, or metabolic disease, unless currently controlled and stable with protocol-allowed medication, within 30 days prior to the first night of run-in study medication.
* Body mass index of less than 18 or greater than 34 (weight /height2).
* Any clinically important abnormal finding as documented by a medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator.
* Positive hepatitis panel.
* Known history of human immunodeficiency virus.
* Any additional conditions(s) that in the investigator's opinion would affect:
* sleep/wake function
* prohibit the subject from completing the study
* indicate that continuation in the study would not be in the best interests of the subject.
* Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication, including:
* Melatonin
* Anxiolytics
* Antipsychotics
* Over-the-counter and prescription sedatives
* Hypnotics (excluding zolpidem)
* Narcotic analgesics
* Antidepressants
* Beta-blockers (exception is that Atenolol is permissible)
* Anticonvulsants
* St. John's wort
* Sedating H1 antihistamines
* Kava-kava
* Systemic steroids
* Ginkgo-biloba
* Respiratory stimulants
* Over-the-counter and prescription diet aids
* Sedating Decongestants
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Takeda Global Research & Development Center, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director Clinical Science
Role: STUDY_DIRECTOR
Takeda Global Research & Development Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hot Springs, Arkansas, United States
Anaheim, California, United States
Fountain Valley, California, United States
La Mesa, California, United States
Los Angeles, California, United States
Redlands, California, United States
San Diego, California, United States
San Francisco, California, United States
Santa Monica, California, United States
Denver, Colorado, United States
Clearwater, Florida, United States
Hollywood, Florida, United States
Kissimmee, Florida, United States
Naples, Florida, United States
Pembroke Pines, Florida, United States
Winter Park, Florida, United States
Atlanta, Georgia, United States
Austell, Georgia, United States
Boise, Idaho, United States
Louisville, Kentucky, United States
Metairie, Louisiana, United States
Chevy Chase, Maryland, United States
St Louis, Missouri, United States
Lincoln, Nebraska, United States
New York, New York, United States
West Seneca, New York, United States
Raleigh, North Carolina, United States
Wilmington, North Carolina, United States
Cincinnati, Ohio, United States
Toledo, Ohio, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Greer, South Carolina, United States
Fayetteville, Tennessee, United States
Austin, Texas, United States
Dallas, Texas, United States
Fort Worth, Texas, United States
Houston, Texas, United States
San Angelo, Texas, United States
San Antonio, Texas, United States
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1114-3262
Identifier Type: REGISTRY
Identifier Source: secondary_id
01-06-TL-375-071
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.